Trial · NCT06065670
Registered outcomes48
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 48
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Corpus Callosum Myelin Water Fraction | This will be assessed at the baseline visit. | The efficacy of clemastine relative to placebo at increasing the myelin water fraction (MWF) (measured in %) from magnetic resonance imaging of the corpus callosum. |
| Primary | Change from Baseline in Corpus Callosum Myelin Water Fraction at 3 Months | This will be assessed at the baseline and 3 month visits. | The efficacy of clemastine relative to placebo at increasing the myelin water fraction (MWF) (measured in %) from magnetic resonance imaging of the corpus callosum. Change = (3-month % - Baseline %) |
| Primary | Change from Baseline in Corpus Callosum Myelin Water Fraction at 6 Months | This will be assessed at the baseline and 6 month visits. | The efficacy of clemastine relative to placebo at increasing the myelin water fraction (MWF) (measured in %) from magnetic resonance imaging of the corpus callosum. Change = (6-month % - Baseline %) |
| Primary | Corpus Callosum T1 Relaxation Time | This will be assessed at the baseline visit. | The efficacy of clemastine relative to placebo at shortening the T1 relaxation time (measured in seconds) within the corpus callosum using T1 mapping protocols in an MRI. |
| Primary | Change from Baseline in Corpus Callosum T1 Relaxation Time at 3 Months | This will be assessed at the baseline and 3-month visits. | The efficacy of clemastine relative to placebo at shortening the T1 relaxation time (measured in seconds) within the corpus callosum using T1 mapping protocols in an MRI. (3-month time - Baseline time) |
| Primary | Change from Baseline in Corpus Callosum T1 Relaxation Time at 6 Months | This will be assessed at the baseline and 6-month visits. | The efficacy of clemastine relative to placebo at shortening the T1 relaxation time (measured in seconds) within the corpus callosum using T1 mapping protocols in an MRI. (6-month time - Baseline time) |
| Primary | Corpus Callosum UTE Fraction | This will be assessed at the baseline visit. | The efficacy of clemastine relative to placebo at increasing the ultrashort echo time (UTE) fraction (measured in %) derived from magnetic resonance imaging of the corpus callosum. |
| Primary | Change from Baseline in Corpus Callosum UTE Fraction at 3 Months | This will be assessed at the baseline and 3-month visits. | The efficacy of clemastine relative to placebo at increasing the ultrashort echo time (UTE) fraction (measured in %) derived from magnetic resonance imaging of the corpus callosum. Change = (3-month % - Baseline %) |
| Primary | Change from Baseline in Corpus Callosum UTE Fraction at 6 Months | This will be assessed at the baseline and 6-month visits. | The efficacy of clemastine relative to placebo at increasing the ultrashort echo time (UTE) fraction (measured in %) derived from magnetic resonance imaging of the corpus callosum. Change = (6-month % - Baseline %) |
| Secondary | Optic Radiation Myelin Water Fraction | This will be assessed at the baseline visit. | The efficacy of Clemastine relative to placebo at increasing the MWF (measured in %) of the optic radiation. |
| Secondary | Change from Baseline in Optic Radiation Myelin Water Fraction at 3 Months | This will be assessed at the baseline and 3-month visits. | The efficacy of Clemastine relative to placebo at increasing the MWF (measured in %) of the optic radiation. Change = (3-month % - Baseline %) |
| Secondary | Change from Baseline in Optic Radiation Myelin Water Fraction at 6 Months | This will be assessed at the baseline and 6-month visits. | The efficacy of Clemastine relative to placebo at increasing the MWF (measured in %) of the optic radiation. Change = (6-month % - Baseline %) |
| Secondary | Corticospinal Tract Myelin Water Fraction | This will be assessed at the baseline visit. | The efficacy of clemastine relative to placebo at increasing the MWF (measured in %) of the corticospinal tract. |
| Secondary | Change from Baseline in Corticospinal Tract Myelin Water Fraction at 3 Months | This will be assessed at the baseline and 3-month visits. | The efficacy of clemastine relative to placebo at increasing the MWF (measured in %) of the corticospinal tract. (3-month % - Baseline %) |
| Secondary | Change from Baseline in Corticospinal Tract Myelin Water Fraction at 6 Months | This will be assessed at the baseline and 6-month visits. | The efficacy of clemastine relative to placebo at increasing the MWF (measured in %) of the corticospinal tract. (6-month % - Baseline %) |
| Secondary | Optic Radiation T1 Relaxation time | This will be assessed at the baseline visit. | To evaluate the efficacy of Clemastine relative to placebo at increasing the T1 relaxation time (measured in seconds) of the optic radiation. |
| Secondary | Change from Baseline in Optic Radiation T1 Relaxation time at 3 Months | This will be assessed at the baseline and 3-month visits. | To evaluate the efficacy of Clemastine relative to placebo at increasing the T1 relaxation time (measured in seconds) of the optic radiation. (3-month time - Baseline time) |
| Secondary | Change from Baseline in Optic Radiation T1 Relaxation time at 6 Months | This will be assessed at the baseline and 6-month visits. | To evaluate the efficacy of Clemastine relative to placebo at increasing the T1 relaxation time (measured in seconds) of the optic radiation. (6-month time - Baseline time) |
| Secondary | Corticospinal Tract T1 Relaxation Time | This will be assessed at the baseline visit. | To evaluate the efficacy of Clemastine relative to placebo at increasing the T1 relaxation time (measured in seconds) of the corticospinal tract. |
| Secondary | Change from Baseline in Corticospinal Tract T1 Relaxation Time at 3 Months | This will be assessed at the baseline and 3-month visits. | To evaluate the efficacy of Clemastine relative to placebo at increasing the T1 relaxation time (measured in seconds) of the corticospinal tract. (3-month time - Baseline time) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06065670/registered